series-c-plus
Stage
2
Investors
About
Develops engineered regulatory T cell (Treg) therapies to downregulate pathological immune responses. The company focuses on cell therapy approaches using Tregs to treat immune-mediated diseases.
Explore Quell Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.